<DOC>
	<DOCNO>NCT01377376</DOCNO>
	<brief_summary>The primary objective study determine combination regimen ARQ 197 erlotinib improve overall survival ( OS ) compare erlotinib monotherapy subject locally advance metastatic non-squamous NSCLC wild-type EGFR receive 1 2 prior systemic anti-cancer therapy Intent-to-Treat ( ITT ) population .</brief_summary>
	<brief_title>A Phase 3 , Randomized , Double-Blinded , Placebo-Controlled Study ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female least 20 year age life expectancy ≥ 3 month 2 . Histologically cytologically confirm surgically unresectable locally advanced metastatic ( stage IIIB/IV ) nonsquamous NSCLC wildtype ( exclude major activate mutation ( exon 19 deletion and/or exon 21 L858R mutation ) ) EGFR gene status confirm highly sensitive PCR assay 3 . Evaluable disease accord RECIST , Version 1.1 4 . Received one two prior line systemic anticancer therapy advance metastatic disease , one must platinumbased therapy 5 . ECOG performance status 0 1 6 . Demonstrate adequate bone marrow , liver , renal function , define : • ALT AST ≤ 2.5 × upper limit normal ( ULN ) , total bilirubin ≤ 1.5 × ULN , ANC ≥1.5 × 10^9/L , platelet count ≥100 × 10^9/L , hemoglobin ≥9.0 g/dL , serum creatinine ≤1.5 mg/dL . 7 . Voluntary write informed consent form performance studyspecific procedure test Exclusion Criteria 1 . Prior therapy EGFR inhibitor and/or tivantinib 2 . Any systemic antitumor treatment NSCLC investigational agent within 4 week prior randomization 3 . Palliative radiotherapy within 2 week , radiotherapy curative intent target lesion within 8 week chest within 4 week area prior randomization 4 . Major surgical procedure within 4 week prior randomization 5 . History cardiac disease 6 . Known symptomatic brain metastasis 7 . Need breastfeed child within 12 week complete study 8 . Significant gastrointestinal disorder could interfere absorption tivantinib and/or erlotinib 9 . History malignancy NSCLC 10 . Known infection HIV , active HBV HCV 11 . Clinically significant interstitial lung disease detect CT scan prior history diseases 12 . Psychiatric disease could affect informed consent process 13 . Subjects wish child would agree use one contraceptive measure highly effective 14 . Positive serum urine pregnancy test female subject childbearing potential 15 . Any significant comorbid condition , opinion investigator/subinvestigator , would impair study participation cooperation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>